Dibenzothiazyldisulfid

Hauptinformation

  • Handelsname:
  • Dibenzothiazyldisulfid 1%, Testsalbe
  • Darreichungsform:
  • Salbe
  • Zusammensetzung:
  • Bis(1,3-benzothiazol-2-yl)disulfan 8.48mg
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • für die Allgemeinheit:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie das Informationsblatt für die Öffentlichkeit.

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Dibenzothiazyldisulfid 1%, Testsalbe
    Deutschland
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte
  • Zulassungsnummer:
  • PEI.D.04706.01.1
  • Letzte Änderung:
  • 03-02-2018

16-6-2017

 Eleven new substances on the list of euphoriant substances

Eleven new substances on the list of euphoriant substances

On 15 June 2017, 11 new substances were included in annex 1 of executive order no. 557 of 31 May 2011 on euphoriant substances issued by the Danish Ministry of Health. The information is primarily relevant to companies authorised to deal with euphoriant substances. As from 15 June 2017, the following substances are included in schedule B: 0. AB-CHMINACA (N-(1-aminocarbonyl-2-methylpropyl)-1-(cyclohexylmethyl)-1H-indazol-3-carboxamid). 15 b. AMB-FUBINACA (N-(1-methoxycarbonyl-2-methylpropyl)-1-(...

Danish Medicines Agency

18-5-2018

EU/3/17/1936 (Pharma Gateway AB)

EU/3/17/1936 (Pharma Gateway AB)

EU/3/17/1936 (Active substance: 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea) - Transfer of orphan designation - Commission Decision (2018)3133 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/119/17/T/01

Europe -DG Health and Food Safety

3-4-2018

EU/3/12/1080 (AbbVie Deutschland GmbH and Co. KG)

EU/3/12/1080 (AbbVie Deutschland GmbH and Co. KG)

EU/3/12/1080 (Active substance: 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide) - Transfer of orphan designation - Commission Decision (2018)2056 of Tue, 03 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/124/12/T/01

Europe -DG Health and Food Safety

28-3-2018

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Transfer of orphan designation - Commission Decision (2018)2011 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/17/T/01

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/1989 (FGK Representative Service GmbH)

EU/3/18/1989 (FGK Representative Service GmbH)

EU/3/18/1989 (Active substance: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide) - Orphan designation - Commission Decision (2018)1878 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/208/17

Europe -DG Health and Food Safety

21-3-2018

EU/3/17/1861 (Roivant Sciences Ireland Limited)

EU/3/17/1861 (Roivant Sciences Ireland Limited)

EU/3/17/1861 (Active substance: (S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester) - Transfer of orphan designation - Commission Decision (2018)1826 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/299/16/T/01

Europe -DG Health and Food Safety

21-3-2018

EU/3/14/1363 (Quintiles Ireland Limited)

EU/3/14/1363 (Quintiles Ireland Limited)

EU/3/14/1363 (Active substance: 4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid) - Transfer of orphan designation - Commission Decision (2018)1818 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/131/14/T/01

Europe -DG Health and Food Safety

26-2-2018

EU/3/18/1988 (Chiesi Farmaceutici S.p.A.)

EU/3/18/1988 (Chiesi Farmaceutici S.p.A.)

EU/3/18/1988 (Active substance: (R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate) - Orphan designation - Commission Decision (2018)1255 of Mon, 26 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/203/17

Europe -DG Health and Food Safety

26-2-2018

EU/3/18/1982 (ATXA Therapeutics Limited)

EU/3/18/1982 (ATXA Therapeutics Limited)

EU/3/18/1982 (Active substance: N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide) - Orphan designation - Commission Decision (2018)1249 of Mon, 26 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/199/17

Europe -DG Health and Food Safety

26-2-2018

EU/3/18/1974 (Takeda Pharma A/S)

EU/3/18/1974 (Takeda Pharma A/S)

EU/3/18/1974 (Active substance: 6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate) - Orphan designation - Commission Decision (2018)1257 of Mon, 26 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/193/17

Europe -DG Health and Food Safety

26-2-2018

EU/3/18/1972 (CATS Consultants GmbH)

EU/3/18/1972 (CATS Consultants GmbH)

EU/3/18/1972 (Active substance: 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride) - Orphan designation - Commission Decision (2018)1256 of Mon, 26 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/202/17

Europe -DG Health and Food Safety

6-2-2018

EU/3/07/478 (ICON Clinical Research Limited)

EU/3/07/478 (ICON Clinical Research Limited)

EU/3/07/478 (Active substance: N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide) - Transfer of orphan designation - Commission Decision (2018)697 of Tue, 06 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/053/07/T/03

Europe -DG Health and Food Safety

5-2-2018

EU/3/07/526 (ICON Clinical Research Limited)

EU/3/07/526 (ICON Clinical Research Limited)

EU/3/07/526 (Active substance: N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide) - Transfer of orphan designation - Commission Decision (2018)698 of Mon, 05 Feb 2018 European Medicines Agency (EMA) procedure number: EMA/OD/099/07/T/03

Europe -DG Health and Food Safety

14-12-2017

EU/3/17/1946 (FGK Representative Service GmbH)

EU/3/17/1946 (FGK Representative Service GmbH)

EU/3/17/1946 (Active substance: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide) - Orphan designation - Commission Decision (2017)8778 of Thu, 14 Dec 2017 European Medicines Agency (EMA) procedure number: EMA/OD/156/17

Europe -DG Health and Food Safety

4-12-2017

EU/3/15/1606 (Loxo Oncology Limited)

EU/3/15/1606 (Loxo Oncology Limited)

EU/3/15/1606 (Active substance: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) - Transfer of orphan designation - Commission Decision (2017)8248 of Mon, 04 Dec 2017 European Medicines Agency (EMA) procedure number: EMA/OD/184/15/T/01

Europe -DG Health and Food Safety

10-11-2017

EU/3/17/1933 (Quintiles Ireland Limited)

EU/3/17/1933 (Quintiles Ireland Limited)

EU/3/17/1933 (Active substance: (1'R,6'R)-3-(benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione) - Orphan designation - Commission Decision (2017)7555 of Fri, 10 Nov 2017 European Medicines Agency (EMA) procedure number: EMA/OD/142/17

Europe -DG Health and Food Safety

10-11-2017

EU/3/17/1942 (Celleron Therapeutics Limited)

EU/3/17/1942 (Celleron Therapeutics Limited)

EU/3/17/1942 (Active substance: N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide) - Orphan designation - Commission Decision (2017)7564 of Fri, 10 Nov 2017 European Medicines Agency (EMA) procedure number: EMA/OD/121/17

Europe -DG Health and Food Safety

10-11-2017

EU/3/17/1937 (Quintiles Ireland Limited)

EU/3/17/1937 (Quintiles Ireland Limited)

EU/3/17/1937 (Active substance: 4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one) - Orphan designation - Commission Decision (2017)7559 of Fri, 10 Nov 2017 European Medicines Agency (EMA) procedure number: EMA/OD/118/17

Europe -DG Health and Food Safety

10-11-2017

EU/3/17/1936 (Worldwide Clinical Trials Limited)

EU/3/17/1936 (Worldwide Clinical Trials Limited)

EU/3/17/1936 (Active substance: 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea) - Orphan designation - Commission Decision (2017)7558 of Fri, 10 Nov 2017 European Medicines Agency (EMA) procedure number: EMA/OD/119/17

Europe -DG Health and Food Safety

18-10-2017

EU/3/17/1916 (Voisin Consulting S.A.R.L.)

EU/3/17/1916 (Voisin Consulting S.A.R.L.)

EU/3/17/1916 (Active substance: 5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate]) - Orphan designation - Commission Decision (2017)7049 of Wed, 18 Oct 2017 European Medicines Agency (EMA) procedure number: EMA/OD/124/17

Europe -DG Health and Food Safety

7-9-2017

EU/3/03/182 (Idorsia Pharmaceuticals Deutschland GmbH)

EU/3/03/182 (Idorsia Pharmaceuticals Deutschland GmbH)

EU/3/03/182 (Active substance: 5-methyl-pyridine-2-sulfonic acid {6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt) - Transfer of orphan designation - Commission Decision (2017)6106 of Thu, 07 Sep 2017 European Medicines Agency (EMA) procedure number: EMEA/OD/057/03/T/02

Europe -DG Health and Food Safety

30-8-2017

EU/3/07/518 (Bayer AG)

EU/3/07/518 (Bayer AG)

EU/3/07/518 (Active substance: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate) - Transfer of orphan designation - Commission Decision (2017)5980 of Wed, 30 Aug 2017 European Medicines Agency (EMA) procedure number: EMEA/OD/088/07/T/02

Europe -DG Health and Food Safety

25-8-2017

EU/3/17/1902 (Eisai Europe Limited)

EU/3/17/1902 (Eisai Europe Limited)

EU/3/17/1902 (Active substance: N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide) - Orphan designation - Commission Decision (2017)5911 of Fri, 25 Aug 2017 European Medicines Agency (EMA) procedure number: EMA/OD/052/17

Europe -DG Health and Food Safety

19-7-2017

EU/3/17/1889 (PhaRA bvba)

EU/3/17/1889 (PhaRA bvba)

EU/3/17/1889 (Active substance: (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine) - Orphan designation - Commission Decision (2017)5153 of Wed, 19 Jul 2017 European Medicines Agency (EMA) procedure number: EMA/OD/037/17

Europe -DG Health and Food Safety